On October 10, 2024, the Food and Drug Administration (FDA) approved Inavolisib, in combination with Palbociclib and Fulvestrant, for adults with advanced breast cancer that meets specific criteria. This approval is essential for patients who have:Endocrine-resistant breast cancerPIK3CA-mutated tumorsHormone receptor (HR)-positive statusHER2-negative statusLocally advanced or metastatic disease, as identified by an FDA-approved...